Comparative Pharmacology
Head-to-head clinical analysis: HALOTESTIN versus TESTOSTERONE UNDECANOATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTESTIN versus TESTOSTERONE UNDECANOATE.
HALOTESTIN vs TESTOSTERONE UNDECANOATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
Testosterone undecanoate is a prodrug of testosterone, which binds to androgen receptors (ARs) in target tissues, leading to activation of androgen-responsive genes that promote male sexual development, maintenance of secondary sexual characteristics, and anabolic effects. It also exerts negative feedback on the hypothalamic-pituitary-gonadal axis, suppressing gonadotropin secretion.
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
1000 mg intramuscularly every 10-14 weeks, followed by a second dose at 6 weeks; maintenance 1000 mg every 10-14 weeks.
None Documented
None Documented
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
Terminal elimination half-life: 20.7 days (range 16.5–25.7 days) after intramuscular injection. This prolonged half-life is due to slow release from the oily depot in muscle. With oral administration, half-life is approximately 7–13 hours.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Renal (5-10% as glucuronide and sulfate conjugates, <1% as unchanged testosterone), Fecal (90% as metabolites via bile). No significant biliary excretion of active drug.
Category C
Category D/X
Androgen
Androgen